PALM BEACH GARDENS, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“we,” “our,” “GEG,” “Great Elm,” or “the Company”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal third quarter ended March 31, 2024.
Fiscal Third Quarter 2024 and Other Recent Highlights
Management Commentary
Jason Reese, Chief Executive Officer of the Company, stated, “We continue to make solid progress in the quarter with respect to our long-term growth strategy. Completing successful capital raises of nearly $60 million at GECC, we are positioned to significantly grow our overall assets under management and related fee revenue. Additionally, GECC’s continued performance allowed Great Elm to earn incentive fees for the fourth consecutive quarter. At Monomoy, I’m increasingly encouraged by our growing backlog of build-to-suit projects, as well as the launch of a new construction management consulting business supported by our seasoned team and anchored by a key tenant contract. Upon the anticipated sale of our first build-to-suit property in fiscal fourth quarter, we will have created value for shareholders and believe we will be able to generate additional shareholder value over time by executing on our considerable BTS pipeline.”
“Furthermore, we are committed to utilizing our strong and liquid balance sheet to grow and diversify our businesses and revenue streams. Overall, we remain focused on scaling our core credit and real estate businesses, launching new investment funds and deploying capital into attractive platform opportunities that offer compelling risk-adjusted returns for our shareholders.”
Capital Raises to Scale the Credit Platform
In February 2024, GECC raised $24 million of equity capital from a special purchase vehicle (“SPV”) that acquired GECC common stock at net asset value. GEG supported the capital raise by making a $6 million investment into the SPV with a large institutional investor that invested $18 million.
In April 2024, GECC completed an underwritten public offering of $34.5 million 8.50% notes due 2029 (“GECCI”).
Discussion of Financial Results for the Fiscal Third Quarter Ended March 31, 2024
GEG reported total revenue of $2.8 million, a 47% increase from $1.9 million in the prior-year period, primarily driven by the collection of incentive fees from GECC of $0.7 million.
GEG recorded net loss from continuing operations of ($2.9) million, compared to a net loss of ($0.5) million in the prior-year period. Net loss in the quarter was driven by an approximately ($2.9) million unrealized loss on our investment in Great Elm Strategic Partnership I, LLC during the quarter.
GEG recorded Adjusted EBITDA of $1.2 million, compared to an Adjusted EBITDA loss of ($0.3) million in the prior-year period.
Stock Repurchase Program
In the fiscal second quarter, GEG’s Board of Directors approved a stock repurchase program under which GEG is authorized to repurchase up to $10 million in the aggregate of its outstanding common stock in the open market. To date, the Company has repurchased a modest number of shares.
Fiscal 2024 Third Quarter Conference Call & Webcast Information
When: | Thursday, May 9, 2024, 8:30 a.m. Eastern Time (ET) |
Call: | All interested parties are invited to participate in the conference call by dialing +1 (888) 440-4537; international callers should dial +1 (646) 960-0669. Participants should enter the Conference ID 2595129 when asked. |
Webcast: | The conference call will be webcast simultaneously and can be accessed here. A copy of the slide presentation accompanying the conference call, can be found here. |
About Great Elm Group, Inc.
Great Elm Group, Inc. (NASDAQ: GEG) is a publicly-traded, alternative asset manager focused on growing a scalable and diversified portfolio of long-duration and permanent capital vehicles across credit, real estate, specialty finance, and other alternative strategies. Great Elm Group, Inc. and its subsidiaries currently manage Great Elm Capital Corp., a publicly-traded business development company, and Monomoy Properties REIT, LLC, an industrial-focused real estate investment trust, in addition to other investments. Great Elm Group, Inc.’s website can be found at www.greatelmgroup.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Statements in this press release that are “forward-looking” statements, including statements regarding expected growth, profitability, acquisition opportunities and outlook involve risks and uncertainties that may individually or collectively impact the matters described herein. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made and represent Great Elm’s assumptions and expectations in light of currently available information. These statements involve risks, variables and uncertainties, and Great Elm’s actual performance results may differ from those projected, and any such differences may be material. For information on certain factors that could cause actual events or results to differ materially from Great Elm’s expectations, please see Great Elm’s filings with the Securities and Exchange Commission (“SEC”), including its most recent annual report on Form 10-K and subsequent reports on Forms 10-Q and 8-K. Additional information relating to Great Elm’s financial position and results of operations is also contained in Great Elm’s annual and quarterly reports filed with the SEC and available for download at its website www.greatelmgroup.com or at the SEC website www.sec.gov.
Non-GAAP Financial Measures
The SEC has adopted rules to regulate the use in filings with the SEC, and in public disclosures, of financial measures that are not in accordance with US GAAP, such as adjusted earnings before interest, taxes, depreciation and amortization (“Adjusted EBITDA”). Adjusted EBITDA is derived from methodologies other than in accordance with US GAAP. Great Elm believes that Adjusted EBITDA is an important measure for investors to use in evaluating Great Elm’s businesses. In addition, Great Elm’s management reviews Adjusted EBITDA as they evaluate acquisition opportunities.
Adjusted EBITDA has limitations as an analytical tool, and you should not consider it either in isolation from, or as a substitute for, analyzing Great Elm’s results as reported under US GAAP. Non-GAAP financial measures reported by Great Elm may not be comparable to similarly titled amounts reported by other companies.
Included in the financial tables below is a reconciliation of Adjusted EBITDA to the most directly comparable US GAAP financial measure, net income from continuing operations.
Endnotes
1 Pro forma FPAUM assumes full investment of incremental capital.
Media & Investor Contact:
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
Great Elm Group, Inc.
Condensed Consolidated Balance Sheets (Unaudited)
Dollar amounts in thousands (except per share data)
ASSETS | March 31, 2024 | June 30, 2023 | ||||||
Current assets | ||||||||
Cash and cash equivalents | $ | 44,085 | $ | 60,165 | ||||
Receivables from managed funds | 4,400 | 3,308 | ||||||
Investments in marketable securities | 24,789 | 24,595 | ||||||
Investments, at fair value (cost $46,199 and $40,387, respectively) | 38,244 | 32,611 | ||||||
Prepaid and other current assets | 2,843 | 717 | ||||||
Real estate under development | 8,104 | 1,742 | ||||||
Assets of Consolidated Funds: | ||||||||
Cash and cash equivalents | 5,414 | - | ||||||
Investments, at fair value (cost $8,353) | 8,561 | - | ||||||
Other assets | 233 | - | ||||||
Total current assets | 136,673 | 123,138 | ||||||
Identifiable intangible assets, net | 11,300 | 12,115 | ||||||
Right-of-use assets | 230 | 497 | ||||||
Other assets | 150 | 143 | ||||||
Total assets | $ | 148,353 | $ | 135,893 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities | ||||||||
Accounts payable | $ | 608 | $ | 191 | ||||
Accrued expenses and other current liabilities | 4,276 | 5,418 | ||||||
Payable for securities purchased | 4,914 | - | ||||||
Current portion of related party payables | 618 | 1,409 | ||||||
Current portion of lease liabilities | 183 | 359 | ||||||
Liabilities of Consolidated Funds: | ||||||||
Payable for securities purchased | 267 | - | ||||||
Accrued expenses and other liabilities | 124 | - | ||||||
Total current liabilities | 10,990 | 7,377 | ||||||
Lease liabilities, net of current portion | 26 | 142 | ||||||
Long-term debt (face value $26,945) | 26,019 | 25,808 | ||||||
Related party payables, net of current portion | - | 926 | ||||||
Convertible notes (face value $38,859 and $37,912, including $15,780 and $15,395 held by related parties, respectively) | 38,164 | 37,129 | ||||||
Other liabilities | 683 | 669 | ||||||
Total liabilities | 75,882 | 72,051 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity | ||||||||
Preferred stock, $0.001 par value; 5,000,000 authorized and zero outstanding | - | - | ||||||
Common stock, $0.001 par value; 350,000,000 shares authorized and 31,881,695 shares issued and 30,164,142 outstanding at March 31, 2024; and 30,651,047 shares issued and 29,546,655 outstanding at June 30, 2023 | 30 | 30 | ||||||
Additional paid-in-capital | 3,317,212 | 3,315,378 | ||||||
Accumulated deficit | (3,252,242 | ) | (3,251,566 | ) | ||||
Total Great Elm Group, Inc. stockholders' equity | 65,000 | 63,842 | ||||||
Non-controlling interests | 7,471 | - | ||||||
Total stockholders' equity | 72,471 | 63,842 | ||||||
Total liabilities and stockholders' equity | $ | 148,353 | $ | 135,893 | ||||
Great Elm Group, Inc.
Condensed Consolidated Statements of Operations (Unaudited)
Amounts in thousands (except per share data)
For the three months ended March 31, | For the nine months ended March 31, | ||||||||||||||
2024 | 2023 | 2024 | 2023 | ||||||||||||
Revenues | $ | 2,787 | $ | 1,898 | $ | 8,916 | $ | 5,637 | |||||||
Operating costs and expenses: | |||||||||||||||
Investment management expenses | 2,733 | 2,593 | 8,334 | 6,893 | |||||||||||
Depreciation and amortization | 271 | 281 | 837 | 870 | |||||||||||
Selling, general and administrative | 1,630 | 1,893 | 5,738 | 5,441 | |||||||||||
Expenses of Consolidated Funds | 22 | - | 22 | 46 | |||||||||||
Total operating costs and expenses | 4,656 | 4,767 | 14,931 | 13,250 | |||||||||||
Operating loss | (1,869 | ) | (2,869 | ) | (6,015 | ) | (7,613 | ) | |||||||
Dividends and interest income | 2,359 | 1,520 | 6,417 | 4,432 | |||||||||||
Net realized and unrealized gain (loss) on investments | (2,753 | ) | 1,989 | 1,735 | 17,434 | ||||||||||
Net realized and unrealized gain (loss) on investments of Consolidated Funds | 131 | - | 245 | (16 | ) | ||||||||||
Interest and other income of Consolidated Funds | 323 | - | 451 | - | |||||||||||
Gain on sale of controlling interest in subsidiary | - | - | - | 10,524 | |||||||||||
Interest expense | (1,074 | ) | (1,095 | ) | (3,197 | ) | (5,024 | ) | |||||||
(Loss) income before income taxes from continuing operations | (2,883 | ) | (455 | ) | (364 | ) | 19,737 | ||||||||
Income tax benefit (expense) | - | - | - | (2 | ) | ||||||||||
Net (loss) income from continuing operations | (2,883 | ) | (455 | ) | (364 | ) | 19,735 | ||||||||
Discontinued operations: | |||||||||||||||
Net income from discontinued operations | - | 12,203 | 16 | 13,202 | |||||||||||
Net (loss) income | $ | (2,883 | ) | $ | 11,748 | $ | (348 | ) | $ | 32,937 | |||||
Less: net income (loss) attributable to non-controlling interest, continuing operations | 217 | - | 328 | (1,554 | ) | ||||||||||
Less: net income attributable to non-controlling interest, discontinued operations | - | - | - | 1,504 | |||||||||||
Net (loss) income attributable to Great Elm Group, Inc. | $ | (3,100 | ) | $ | 11,748 | $ | (676 | ) | $ | 32,987 | |||||
Basic net income (loss) per share from: | |||||||||||||||
Continuing operations | $ | (0.10 | ) | $ | (0.02 | ) | $ | (0.02 | ) | $ | 0.74 | ||||
Discontinued operations | - | 0.42 | - | 0.41 | |||||||||||
Basic net income (loss) per share | $ | (0.10 | ) | $ | 0.40 | $ | (0.02 | ) | $ | 1.15 | |||||
Diluted net income (loss) per share from: | |||||||||||||||
Continuing operations | $ | (0.10 | ) | $ | (0.02 | ) | $ | (0.02 | ) | $ | 0.56 | ||||
Discontinued operations | - | 0.42 | - | 0.29 | |||||||||||
Diluted net income (loss) per share | $ | (0.10 | ) | $ | 0.40 | $ | (0.02 | ) | $ | 0.85 | |||||
Weighted average shares outstanding | |||||||||||||||
Basic | 30,066 | 28,997 | 29,844 | 28,779 | |||||||||||
Diluted | 30,066 | 28,997 | 29,844 | 40,673 | |||||||||||
Great Elm Group, Inc.
Reconciliation from Net Income (Loss) from Continuing Operations to Adjusted EBITDA
Dollar amounts in thousands
For the three months ended March 31, | For the nine months ended March 31, | |||||||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||||||
Net Income (Loss) from Continuing Operations – GAAP | $ | (2,883 | ) | $ | (455 | ) | $ | (364 | ) | $ | 19,735 | |||||||||
Interest expense | 1,074 | 1,095 | 3,197 | 5,024 | ||||||||||||||||
Income tax expense (benefit) | - | - | 2 | |||||||||||||||||
Depreciation and amortization | 271 | 281 | 837 | 870 | ||||||||||||||||
Non-cash compensation | 698 | 660 | 2,426 | 2,246 | ||||||||||||||||
(Gain) loss on investments | 2,622 | (1,964 | ) | (1,980 | ) | 6,980 | ||||||||||||||
Gains related to sale of Forest | - | (25 | ) | - | (34,922 | ) | ||||||||||||||
Transaction and integration related costs(1) | - | - | - | 471 | ||||||||||||||||
Change in contingent consideration | (554 | ) | 120 | (518 | ) | 180 | ||||||||||||||
Adjusted EBITDA(2) | $ | 1,228 | $ | (288 | ) | $ | 3,598 | $ | 586 | |||||||||||
(1) Transaction and integration-related costs include costs to sell, acquire and integrate acquired businesses. | ||||||||||||||||||||
(2) Adjusted EBITDA for prior periods has been adjusted to include dividend income earned during such periods consistent with the methodology for March 31, 2024. | ||||||||||||||||||||
Last Trade: | US$1.78 |
Daily Volume: | 101,606 |
Market Cap: | US$54.270M |
November 11, 2024 February 13, 2024 November 08, 2023 September 20, 2023 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB